{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T21:27:55Z","timestamp":1782941275989,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s41030-025-00295-1","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T03:54:42Z","timestamp":1743825282000},"page":"117-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of Surgery in Pleural Mesothelioma: A Journey through the Evidence, MARS 2 and Beyond"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0859-5550","authenticated-orcid":false,"given":"Avinash","family":"Aujayeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Astoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Londero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zuin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"6","key":"295_CR1","doi-asserted-by":"publisher","first-page":"00467","DOI":"10.1183\/23120541.00467-2023","volume":"9","author":"RJH Conway","year":"2023","unstructured":"Conway RJH, Smith N, Cooper W, ASSESS-meso Collaborative group, et al. Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort. ERJ Open Res. 2023;9(6):00467\u20132023.","journal-title":"ERJ Open Res"},{"issue":"5","key":"295_CR2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","volume":"17","author":"JL Sauter","year":"2022","unstructured":"Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification. J Thorac Oncol. 2022;17(5):608\u201322.","journal-title":"J Thorac Oncol"},{"key":"295_CR3","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","volume":"73","author":"I Woolhouse","year":"2018","unstructured":"Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73:i1\u201330.","journal-title":"Thorax"},{"issue":"1","key":"295_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/thx.31.1.15","volume":"31","author":"EG Butchart","year":"1976","unstructured":"Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax. 1976;31(1):15\u201324. https:\/\/doi.org\/10.1136\/thx.31.1.15.","journal-title":"Thorax"},{"key":"295_CR5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S0140-6736(14)60418-9","volume":"384","author":"RC Rintoul","year":"2014","unstructured":"Rintoul RC, Ritchie AJ, Edwards JG, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384:1118\u201327.","journal-title":"Lancet"},{"key":"295_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/thoraxjnl-2021-218214","volume":"78","author":"AG Dawson","year":"2023","unstructured":"Dawson AG, Kutywayo K, Mohammed SB, et al. Cytoreductive surgery with hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma: a systematic review. Thorax. 2023;78:409\u201317.","journal-title":"Thorax"},{"key":"295_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"key":"295_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","volume":"12","author":"E Lim","year":"2024","unstructured":"Lim E, Waller D, Lau K, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024;12:457\u201366.","journal-title":"Lancet Respir Med"},{"key":"295_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","volume":"12","author":"T Treasure","year":"2011","unstructured":"Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12:763\u201372.","journal-title":"Lancet Oncol"},{"issue":"13","key":"295_CR10","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","volume":"36","author":"HL Kindler","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(13):1343\u201373.","journal-title":"J Clin Oncol"},{"key":"295_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","volume":"196","author":"RR Meyerhoff","year":"2015","unstructured":"Meyerhoff RR, Yang CF, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database. J Surg Res. 2015;196:23\u201332.","journal-title":"J Surg Res"},{"key":"295_CR12","doi-asserted-by":"publisher","first-page":"12208","DOI":"10.1002\/cam4.5915","volume":"12","author":"P Bou-Samra","year":"2023","unstructured":"Bou-Samra P, Chang A, Azari F, et al. Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: a review of the National Cancer Database. Cancer Med. 2023;12:12208\u201320. https:\/\/doi.org\/10.1002\/cam4.5915.","journal-title":"Cancer Med"},{"issue":"1","key":"295_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.athoracsur.2024.02.022","volume":"118","author":"A Nakamura","year":"2024","unstructured":"Nakamura A, Hashimoto M, Kuroda A, et al. Impact of operation on disease progression and survival of patients with pleural mesothelioma. Ann Thorac Surg. 2024;118(1):216\u201323. https:\/\/doi.org\/10.1016\/j.athoracsur.2024.02.022.","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"295_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ejcts\/ezaa158","volume":"58","author":"I Opitz","year":"2020","unstructured":"Opitz I, Scherpereel A, Berghmans T, et al. ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2020;58(1):1\u201324.","journal-title":"Eur J Cardiothorac Surg"},{"key":"295_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/JTO.0000000000000064","volume":"9","author":"P Bovolato","year":"2014","unstructured":"Bovolato P, Casadio C, Bill\u00e8 A, et al. Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014;9:390\u20136.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"295_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.6004\/jnccn.2024.0014","volume":"22","author":"J Stevenson","year":"2024","unstructured":"Stevenson J, Ettinger DS, Wood DE, et al. NCCN Guidelines\u00ae insights: mesothelioma: pleural, version 1.2024. J Natl Compr Canc Netw. 2024;22(2):72\u201381.","journal-title":"J Natl Compr Canc Netw"},{"key":"295_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/09031936.00063109","volume":"35","author":"A Scherpereel","year":"2010","unstructured":"Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J. 2010;35:479\u201395.","journal-title":"Eur Respir J"},{"issue":"6","key":"295_CR18","doi-asserted-by":"publisher","first-page":"1900953","DOI":"10.1183\/13993003.00953-2019","volume":"55","author":"A Scherpereel","year":"2020","unstructured":"Scherpereel A, Opitz I, Berghmans T, et al. ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953. https:\/\/doi.org\/10.1183\/13993003.00953-2019.","journal-title":"Eur Respir J"},{"issue":"1171","key":"295_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1136\/postgradmedj-2021-141200","volume":"99","author":"R Davidson","year":"2023","unstructured":"Davidson R, Carling M, Jackson K, et al. Indwelling pleural catheters: evidence for and management. Postgrad Med J. 2023;99(1171):416\u201322. https:\/\/doi.org\/10.1136\/postgradmedj-2021-141200.","journal-title":"Postgrad Med J"},{"key":"295_CR20","doi-asserted-by":"publisher","first-page":"e038892","DOI":"10.1136\/bmjopen-2020-038892","volume":"10","author":"E Lim","year":"2020","unstructured":"Lim E, Darlison L, Edwards J, et al. Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open. 2020;10:e038892. https:\/\/doi.org\/10.1136\/bmjopen-2020-038892.","journal-title":"BMJ Open"},{"key":"295_CR21","doi-asserted-by":"publisher","first-page":"1800349","DOI":"10.1183\/13993003.00349-2018","volume":"52","author":"AC Bibby","year":"2018","unstructured":"Bibby AC, Dorn P, Psallidas I, et al. ERS\/EACTS statement on the management of malignant pleural effusions. Eur Respir J. 2018;52:1800349.","journal-title":"Eur Respir J"},{"key":"295_CR22","doi-asserted-by":"publisher","first-page":"1900953","DOI":"10.1183\/13993003.00953-2019","volume":"55","author":"A Scherpereel","year":"2020","unstructured":"Scherpereel A, Scherpereel A, Opitz I, et al. ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55:1900953.","journal-title":"Eur Respir J"},{"key":"295_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:129\u201342.","journal-title":"Ann Oncol"},{"key":"295_CR24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1470-2045(20)30606-9","volume":"22","author":"BCJ Cho","year":"2021","unstructured":"Cho BCJ, Donahoe L, Bradbury PA, et al. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol. 2021;22:190\u20137.","journal-title":"Lancet Oncol"},{"key":"295_CR25","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/SLA.0000000000004306","volume":"275","author":"M Lapidot","year":"2022","unstructured":"Lapidot M, Gill RR, Mazzola E, et al. Pleurectomy decortication in the treatment of malignant pleural mesothelioma: encouraging results and novel prognostic implications based on experience in 355 consecutive patients. Ann Surg. 2022;275:1212\u201320.","journal-title":"Ann Surg"},{"key":"295_CR26","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.jtcvs.2021.07.017","volume":"163","author":"S Hasegawa","year":"2022","unstructured":"Hasegawa S, Yokoi K, Okada M, et al. Neoadjuvant pemetrexed plus cisplatin followed by pleurectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2022;163:1940\u20137.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"295_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lungcan.2012.10.017","volume":"79","author":"E Roca","year":"2013","unstructured":"Roca E, Laroumagne S, Vandemoortele T, et al. 18F-fluoro-2-deoxy-d-glucose positron emission tomography\/computed tomography fused imaging in malignant mesothelioma patients: looking from outside is not enough. Lung Cancer. 2013;79:187\u201390.","journal-title":"Lung Cancer"},{"key":"295_CR28","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.3390\/curroncol31090368","volume":"31","author":"E Roca","year":"2024","unstructured":"Roca E, Aujayeb A, Astoul P. Diagnosis of pleural mesothelioma: is everything solved at the present time? Curr Oncol. 2024;31:4968\u201383.","journal-title":"Curr Oncol"},{"key":"295_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1159\/000381922","volume":"89","author":"V Pinelli","year":"2015","unstructured":"Pinelli V, Roca E, Lucchini S, et al. Positron emission tomography\/computed tomography for the pleural staging of malignant pleural mesothelioma: how accurate is it? Respiration. 2015;89:558\u201364.","journal-title":"Respiration"},{"issue":"24","key":"295_CR30","doi-asserted-by":"publisher","first-page":"00050","DOI":"10.1053\/j.semtcvs.2024.07.001","volume":"S1043\u20130679","author":"S Gulati","year":"2024","unstructured":"Gulati S, Wolf AS, Flores RM. Should treatment of mesothelioma include surgery? MARS2 fails to land. Semin Thorac Cardiovasc Surg. 2024;S1043\u20130679(24):00050\u20139. https:\/\/doi.org\/10.1053\/j.semtcvs.2024.07.001.","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"Suppl 1","key":"295_CR31","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.21037\/tlcr.2020.01.08","volume":"9","author":"GA Woodard","year":"2020","unstructured":"Woodard GA, Jablons DM. Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma. Transl Lung Cancer Res. 2020;9(Suppl 1):S86\u201391. https:\/\/doi.org\/10.21037\/tlcr.2020.01.08.","journal-title":"Transl Lung Cancer Res"},{"issue":"2","key":"295_CR32","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jtcvs.2015.09.129","volume":"151","author":"M de Perrot","year":"2016","unstructured":"de Perrot M, Feld R, Leighl NB, Hope A, Waddell TK, Keshavjee S, Cho BC. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2016;151(2):468\u201373. https:\/\/doi.org\/10.1016\/j.jtcvs.2015.09.129.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"295_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/JTO.0000000000000078","volume":"9","author":"J Cho","year":"2014","unstructured":"Cho J, et al. A feasibility study evaluating surgery for mesothelioma after radiation therapy the \u201cSMART\u201d approach for resectable malignant pleural mesothelioma. J Thorac Oncol. 2014;9:397\u2013402.","journal-title":"J Thorac Oncol"},{"key":"295_CR34","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.3390\/cancers14246063","volume":"14","author":"M Gemelli","year":"2022","unstructured":"Gemelli M, Cortinovis DL, Baggi A, et al. Immune checkpoint inhibitors in malignant pleural mesothelioma: a systematic review and meta-analysis. Cancers (Basel). 2022;14:6063.","journal-title":"Cancers (Basel)"},{"key":"295_CR35","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33:488\u201399.","journal-title":"Ann Oncol"},{"key":"295_CR36","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(24)00111-5","volume":"12","author":"KG Blyth","year":"2024","unstructured":"Blyth KG, Adusumilli PS, Astoul P, et al. Leveraging the pleural space for anticancer therapies in pleural mesothelioma. Lancet Respir Med. 2024;12:476\u201383.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"295_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/JTO.0b013e31827740f0","volume":"8","author":"DR Gomez","year":"2013","unstructured":"Gomez DR, Hong DS, Allen PK, Welsh JS, Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R, Rice DC. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8(2):238\u201345. https:\/\/doi.org\/10.1097\/JTO.0b013e31827740f0.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"295_CR38","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.21037\/jtd.2019.04.93","volume":"11","author":"LV Klotz","year":"2019","unstructured":"Klotz LV, Lindner M, Eichhorn ME, et al. Pleurectomy\/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma. J Thorac Dis. 2019;11(5):1963\u201372.","journal-title":"J Thorac Dis"},{"issue":"4","key":"295_CR39","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.jtcvs.2012.12.037","volume":"145","author":"DJ Sugarbaker","year":"2013","unstructured":"Sugarbaker DJ, Gill RR, Yeap BY, et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013;145(4):955\u201363.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"4","key":"295_CR40","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0022-5223(99)70297-7","volume":"117","author":"GB Ratto","year":"1999","unstructured":"Ratto GB, Civalleri D, Esposito M, et al. Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study. J Thorac Cardiovasc Surg. 1999;117(4):759\u201365.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"7","key":"295_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/jso.23321","volume":"107","author":"M Ried","year":"2013","unstructured":"Ried M, Potzger T, Braune N, et al. Local and systemic exposure of cisplatin during hyperthermic intrathoracic chemotherapy perfusion after pleurectomy and decortication for treatment of pleural malignancies. J Surg Oncol. 2013;107(7):735\u201340.","journal-title":"J Surg Oncol"},{"issue":"1","key":"295_CR42","first-page":"171","volume":"7","author":"S Monjanel-Mouterde","year":"2000","unstructured":"Monjanel-Mouterde S, Frenay C, Catalin J, et al. Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions. Oncol Rep. 2000;7(1):171\u20135.","journal-title":"Oncol Rep"},{"key":"295_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16","author":"M Pagano","year":"2022","unstructured":"Pagano M, Alloisio M, Cappuzzo F, et al. Phase III study with atezolizumab versus placebo in patients with malignant pleural mesothelioma after pleurectomy\/decortication (AtezoMeso study). J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16.","journal-title":"J Clin Oncol"},{"key":"295_CR44","unstructured":"Induction chemo+immunotherapy in resectable epithelioid and biphasic pleural mesothelioma (CHIMERA Study) (CHIMERA) https:\/\/clinicaltrials.gov\/study\/NCT06155279. Accessed 09\/02\/2025"},{"key":"295_CR45","unstructured":"Pemetrexed for the treatment of malignant pleural mesothelioma https:\/\/www.nice.org.uk\/guidance\/ta135. Accessed 19\/03\/2025"},{"key":"295_CR46","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405\u201314.","journal-title":"Lancet"},{"key":"295_CR47","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/annonc\/mdz266","volume":"30","author":"G Zalcman","year":"2019","unstructured":"Zalcman G, Mazieres J, Greillier L, et al. Second\/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD). Ann Oncol. 2019;30:747.","journal-title":"Ann Oncol"},{"key":"295_CR48","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","volume":"7","author":"MJ Disselhorst","year":"2019","unstructured":"Disselhorst MJ, Quispel-Janssen J, Lalezari F. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7:260\u201370.","journal-title":"Lancet Respir Med"},{"key":"295_CR49","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","volume":"16","author":"RA Stahel","year":"2015","unstructured":"Stahel RA, Riesterer O, Xyrafas A, et al. Neoadjuvant (chemo)therapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015;16:1651\u20138.","journal-title":"Lancet Oncol"},{"key":"295_CR50","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ijrobp.2015.06.029","volume":"93","author":"E Minatel","year":"2015","unstructured":"Minatel E, Trovo M, Bearz A, et al. Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors. Int J Radiat Oncol Biol Phys. 2015;93:606\u201313.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"295_CR51","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1078-0432.CCR-16-1432","volume":"23","author":"C Tang","year":"2017","unstructured":"Tang C, Welsh JW, de Groot P, et al. Ipilimumab with stereotactic ablative radiation therapy: phase I Results and immunologic correlates from peripheral T cells. Clin Cancer Res. 2017;23:1388\u201396.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"295_CR52","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(24)00111-5","volume":"12","author":"KG Blyth","year":"2024","unstructured":"Blyth KG, Adusumilli PS, Astoul P, et al. Leveraging the pleural space for anticancer therapies in pleural mesothelioma. Lancet Respir Med. 2024;12(6):476\u201383. https:\/\/doi.org\/10.1016\/S2213-2600(24)00111-5.","journal-title":"Lancet Respir Med"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00295-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-025-00295-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00295-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T11:26:49Z","timestamp":1747999609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-025-00295-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["295"],"URL":"https:\/\/doi.org\/10.1007\/s41030-025-00295-1","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Avinash Aujayeb is an Editorial Board member of Pulmonary Therapy. Avinash Aujayeb was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Philippe Astoul, Francesco Londero and Andrea Zuin have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}